Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi et al. · PI Medical Director

Primary endpoint

Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging

Population

Non-Small-Cell Lung Carcinoma; n=616

doi:10.1056/NEJMoa1801005

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The KEYNOTE-189 trial's stated primary conclusion — Pembrolizumab plus chemotherapy improves overall survival in metastatic non-squamous NSCLC without targetable mutations. — replicates in independent cohorts.

oncology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of KEYNOTE-189 are confirming the original effect size in real-world data.

oncology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, pembrolizumab-containing regimens will be first-line for >90% of eligible metastatic non-squamous NSCLC in US practice.

oncology

71%

Semantically related trials

Nearest trials by noeme-centroid cosine distance. Lower = closer.

NCT03036488

0.1434

· 3 claims

Pembrolizumab for Early Triple-Negative Breast Cancer

NCT01844505

0.1560

· 3 claims

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

NCT00829166

0.2128

· 3 claims

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

NCT01958021

0.2139

· 3 claims

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

NCT01035255

0.2511

· 3 claims

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

NCT02386553

0.2611

· 3 claims

An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy